Noliprel (Indapamide, Perindopril Arginine)

Perindopril arginine blocks the angiotensin‑converting enzyme, reducing angiotensin II formation and decreasing vasoconstriction. Indapamide inhibits sodium‑chloride reabsorption in the distal tubule, increasing urine output and lowering peripheral resistance. Together they produce a complementary antihypertensive effect.

The specific dose of Noliprel is determined by the prescribing clinician based on the patient’s blood‑pressure readings, renal function, and overall health status. Dosage adjustments are made according to clinical response and tolerability.

Safety data for Noliprel in pregnancy are limited, and the product is generally avoided unless the potential benefit justifies the risk. Breastfeeding mothers should consult their healthcare provider, as the drug may be excreted in milk.

To request Noliprel, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with single‑agent ACE inhibitors or thiazide diuretics, Noliprel offers a dual mechanism that can achieve greater blood‑pressure reduction with a single tablet, potentially improving adherence. It is an alternative to other combination products such as lisinopril‑hydrochlorothiazide.

Store Noliprel at ambient temperature, below 25 °C, in the original container to protect it from moisture and light. Keep the tablet out of reach of children and do not use after the expiry date.

Noliprel is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew unless instructed otherwise.

Serious risks include angioedema (swelling of the face, lips, tongue, or airway), severe hypotension, acute kidney injury, and hyperkalemia. Patients should seek immediate medical attention if they experience symptoms such as swelling, difficulty breathing, sudden dizziness, or marked decrease in urine output.

Noliprel is contraindicated in patients with known hypersensitivity to either component, those with severe renal impairment, hyperkalemia, or a history of angioedema related to ACE‑inhibitor therapy. It should also be avoided in patients taking aliskiren if they have diabetes.